Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Zavegepant in Migraine Prevention
NCT04804033Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zavegepant in chronic migraine (3 arms), sponsored by Pfizer. Primary endpoint: Mean Change From Observation Phase in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12) at 12 weeks. Started Mar 2021; status: terminated.
02
Drugs
zavegepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT04804033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804033.